Molecular features of responders to nivolumab

AssessedDetectedResponderNon-responderORRP-value
HER2+7116 (23%)1156%0.12
PD-L1+ in tumor cell6014 (23%)8657%< 0.01
CPS≥106017 (28%)61135%0.17
CPS≥16054 (90%)144026%0.15
EBV+684 (6%)1325%0.82
MMR-D688 (12%)6275%< 0.01
TMB≥105432 (59%)72522%0.44
ARID1A mutation525 (10%)1425%0.96
ERBB2 mutation522 (4%)020%0.48
KRAS mutation524 (8%)040%0.31
MET mutation522 (4%)020%0.48
PIK3CA mutation529 (17%)4544%0.03
TP53 mutation5228 (54%)62221%0.66
CCNE1 amplification527 (13%)2529%0.50
ERBB2 amplification529 (17%)090%0.11
FGFR amplification523 (6%)030%0.38
MDM2 amplification522 (4%)020%0.48
MYC amplification523 (6%)030%0.38

CPS combined positive score, EBV Epstein-Barr virus, MMR-D mismatch repair deficient, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, TMB tumor mutation burden